The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1581
ISSUE 1581
September 23, 2019
Glucagon Nasal Powder (Baqsimi) for Severe Hypoglycemia
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
September 23, 2019 (Issue: 1581)
The FDA has approved glucagon nasal powder
(Baqsimi – Lilly) for treatment of severe hypoglycemia
in patients ≥4 years old with diabetes. Baqsimi is the
first noninjectable glucagon formulation to become
available in the US. Injectable glucagon emergency kits
(GlucaGen Hypokit, and generic) have been available
for years, but they require reconstitution of the
lyophilized powder by the caregiver immediately before
injection. An injectable glucagon formulation that does
not require reconstitution was recently approved by the
FDA (Gvoke) and is expected to become available later
in 2019; it will be reviewed in a future issue.
... more
- American Diabetes Association. Introduction: standards of medical care in diabetes – 2019. Diabetes Care 2019; 42:S1.
- MR Rickels et al Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: a randomized crossover noninferiority study. Diabetes Care 2016; 39:264.
- JL Sherr et al. Glucagon nasal powder: a promising alternative to intramuscular glucagon in youth with type 1 diabetes. Diabetes Care 2016; 39:555.
- CB Guzman et al. Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: a randomized clinical trial. Diabetes Obes Metab 2018; 20:646.
- Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. September 5, 2019. Reprinted with permission by First Databank, Inc.

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Glucagon Nasal Powder (Baqsimi) for Severe Hypoglycemia
Article code: 1581b
Electronic, downloadable article - $45
Article code: 1581b
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian